Ketobemidone
Discover related
3 sources
Collated from TripSit, Pharmacology, DrugCentral. Where sources differ (e.g. dosing), Compare shows them side by side.
Also known as kbdTS
An opioid analgesic drug that also acts as an NDMA antagonist. Found to be as potent as morphine in physical side effects, and has high potential for addiction like all opioids do. Overdose may lead to respiratory depression/death. Do not mix with CNS depressants or stimulants. Caution should be used for asthmatic users.TS
Oral
Route dataTripSit
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| — | — | 5–10 mg | 10–15 mg | —+ |
| After-effects | 1–8 hours |
|---|
🧬 Receptor activityDC
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| Delta-type opioid receptor (OPRD1) | — | 6.845 Ki | DRUGCENTRAL | TargetDelta-type opioid receptor (OPRD1) Action— Affinity6.845 Ki SourceDRUGCENTRAL |
| Glutamate receptor ionotropic, NMDA 3A (GRIN3A) | — | 4.585 Ki | DRUGCENTRAL | TargetGlutamate receptor ionotropic, NMDA 3A (GRIN3A) Action— Affinity4.585 Ki SourceDRUGCENTRAL |
| Kappa-type opioid receptor (OPRK1) | — | 6.223 Ki | DRUGCENTRAL | TargetKappa-type opioid receptor (OPRK1) Action— Affinity6.223 Ki SourceDRUGCENTRAL |
| Mu-type opioid receptor (OPRM1) | — | 9 EC50 | DRUGCENTRAL | TargetMu-type opioid receptor (OPRM1) Action— Affinity9 EC50 SourceDRUGCENTRAL |
| Opioid receptor (Oprd1) | — | 8.7 EC50 | DRUGCENTRAL | TargetOpioid receptor (Oprd1) Action— Affinity8.7 EC50 SourceDRUGCENTRAL |
Mechanism of actionPH
Ketobemidone (Cliradon, Ketogan, Ketodur, Cymidon, Ketorax, &c.) is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
Pharmacokinetics
Half-lifePH
Plasma half-life: 2.42 +/- 0.41 h (m +/- SD). Elimination half-life: 3.27 +/- 0.32 h
AbsorptionPH
34% (oral), 44% (rectal)
MetabolismPH
Ketobemidone is mainly metabolised by conjugation of the phenolic hydroxyl group, and by N-desmethylation. Only about 13-24% is excreted unchanged after iv. administration.
Ketobemidone has known human metabolites that include Ketobemidone sulfate, Norketobemidone, and Ketobemidone O-glucuronide.
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.